A multicentre RCT studying the potential benefit of treatments with a direct Factor Xa inhibitor (rivaroxaban) compared with SOC dose subcutaneous LMWH (Lovenox) in hospitalised subjects with COVID‐19. Here, F10 is linked to COVID-19.